NMOSD Abstract Highlights from AAN 2020
Provided by
Support for this activity has been made possible through an educational grant from Alexion Pharmaceuticals, Inc.
Release date: 06/24/20
Expiration date: 07/31/21
NO LONGER AVAILABLE FOR CREDIT
Estimated time to complete: 0.25 hours
Activity Description
Although the 2020 Annual Meeting of the American Academy of Neurology did not take place as scheduled, abstracts including new information and data on neuromyelitis optica spectrum disorder (NMOSD) were published. This CME/CNE activity provides highlights of the latest information about NMOSD and along with expert analysis of its potential clinical relevance for members of the care team in order to help them care for patients with this rare disease.
Note: Since the release of this module, the U.S. Food and Drug Administration approved satralizumab-mwge to treat people with anti-aquaporin-4 (AQP4) antibody positive NMOSD.
Activity Faculty
Michael Levy, MD, PhD
Associate Professor, Harvard Medical School
Director, Neuromyelitis Optica Clinic and Research Laboratory
Research Director, Division of Neuroimmunology & Neuroinfectious Disease
Massachusetts General Hospital
Target Audience
This activity has been designed to meet the educational needs of physicians, nursing professionals and other members of the team caring for patients with NMOSD.
Learning Objectives
After participating in the activity, learners should be better able to:
- Describe the latest research being presented to better manage NMOSD and its clinical relevance

Accreditation and Credit Designation
In support of improving patient care, American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners and Nurses
American Academy of CME, Inc., designates this educational activity for 0.25 ANCC contact hours.
Other members of the care team will receive a certificate of participation.
Disclosure Statement
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosures are as follows:
Dr. Levy has the following relationships to disclose:
- Advisory Board for Scientific Information: Alexion, Viela Bio and Genentech/Roche
- Grant/Research Support (Site PI): Alexion, Viela Bio and Genentech/Roche
Planners for this activity have no relevant financial relationships with any commercial interests.
This activity will review off-label or investigational information.
The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
Method of Participation
There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME/CNE credit for your participation, please complete the post-program assessment. Your certificate can be mailed to you in approximately 30 days.
Hardware/Software Requirements
Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection
Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection
Privacy
For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm. For more information about CheckRare’s privacy policy, please access https://checkrare.com/privacy/
Contact
For any questions, please contact: [email protected]
Copyright
© 2020. This CME/CNE-certified activity is held as copyrighted © by American Academy of CME and CheckRare. Through this notice, the Academy and CheckRare grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).
NMOSD Abstract Highlights from AAN 2020
NMOSD Abstract Highlights from AAN 2020
Provided by
Support for this activity has been made possible through an educational grant from Alexion Pharmaceuticals, Inc.
Release date: 06/24/20
Expiration date: 07/31/21
NO LONGER AVAILABLE FOR CREDIT
Estimated time to complete: 0.25 hours
Activity Description
Although the 2020 Annual Meeting of the American Academy of Neurology did not take place as scheduled, abstracts including new information and data on neuromyelitis optica spectrum disorder (NMOSD) were published. This CME/CNE activity provides highlights of the latest information about NMOSD and along with expert analysis of its potential clinical relevance for members of the care team in order to help them care for patients with this rare disease.
Note: Since the release of this module, the U.S. Food and Drug Administration approved satralizumab-mwge to treat people with anti-aquaporin-4 (AQP4) antibody positive NMOSD.
Activity Faculty
Michael Levy, MD, PhD
Associate Professor, Harvard Medical School
Director, Neuromyelitis Optica Clinic and Research Laboratory
Research Director, Division of Neuroimmunology & Neuroinfectious Disease
Massachusetts General Hospital
Target Audience
This activity has been designed to meet the educational needs of physicians, nursing professionals and other members of the team caring for patients with NMOSD.
Learning Objectives
After participating in the activity, learners should be better able to:
- Describe the latest research being presented to better manage NMOSD and its clinical relevance

Accreditation and Credit Designation
In support of improving patient care, American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners and Nurses
American Academy of CME, Inc., designates this educational activity for 0.25 ANCC contact hours.
Other members of the care team will receive a certificate of participation.
Disclosure Statement
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosures are as follows:
Dr. Levy has the following relationships to disclose:
- Advisory Board for Scientific Information: Alexion, Viela Bio and Genentech/Roche
- Grant/Research Support (Site PI): Alexion, Viela Bio and Genentech/Roche
Planners for this activity have no relevant financial relationships with any commercial interests.
This activity will review off-label or investigational information.
The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
Method of Participation
There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME/CNE credit for your participation, please complete the post-program assessment. Your certificate can be mailed to you in approximately 30 days.
Hardware/Software Requirements
Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection
Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection
Privacy
For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm. For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/
Contact
For any questions, please contact: [email protected]
Copyright
© 2020. This CME/CNE-certified activity is held as copyrighted © by American Academy of CME and CheckRare. Through this notice, the Academy and CheckRare grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).